Merus announces the full validation of its MeMo(R) transgenic mouse for common light chain human antibodies

October 09, 2012

UTRECHT - The Netherlands - October 8, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, announced today the full validation of its transgenic MeMo® mouse for common light chain human antibodies.

The MeMo® mouse creates human antibody diversity using a large repertoire of human heavy chains paired with a common human light chain.

"Over the last year, we have immunized MeMo® mice with half a dozen antigens and analyzed the immune response," said Mark Throsby, COO at Merus. "We are extremely excited by the performance of the MeMo® technology; serum antibody titers as well as size, diversity, functionality and developability of antibody panels are comparable to those of wild type mice."

“In MeMo®, a single human light chain drives the generation of a normal B cell compartment as well as supports a robust immune response,” said Ton Logtenberg, CEO and founder of Merus. “The large and diverse panels of high-quality human antibodies that we retrieve from MeMo® show that this platform is comparable to the best-in-class transgenic platforms using diversified heavy and light chains.”

Because of the common light chain, MeMo®-derived antibodies can be immediately used to rapidly generate thousands of bispecific antibodies (Biclonics™) and combinations of antibodies (Oligoclonics®) for functional screening. Merus has shown that the quality and diversity of common light chain antibodies drives the success of identifying Biclonics™ with unprecedented potencies for application in oncology. The MeMo® mouse is available for licensing.

About Merus B.V.

Merus is a biotechnology company building a pipeline of innovative human bispecific antibodies (BiclonicsTM) and single cell-derived combinations of antibodies (Oligoclonics®) for cancer therapy. Through the use of a common antibody light chain and CH3 heterodimerization technology, these full length IgG antibody therapeutics can be robustly produced at high yields from a single clonal manufacturing cell line using standard approaches. Biclonics™ and Oligoclonics® bind to multiple disease-associated targets such as growth factor receptors expressed by tumor cells. Synergy is achieved by addressing multiple pathways/mechanisms simultaneously, thereby eliminating tumor cells more efficiently and preventing treatment escape.

Merus meets a significant need in the oncology field: the supply of bispecific antibodies and single-cell derived antibody combinations with improved clinical efficacy to address the limited potency of conventional antibodies.

Home > News > Merus announces the full validation of its MeMo...

© 2024 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds